Elisa Petris

Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Invest In Equity is an international force accelerating gender equity to redefine the future of life science investment. By elevating women in investment roles, we’re not just addressing imbalance, we’re building a more resilient, innovative, and impactful investment ecosystem. We unite the investors and industry influencers who recognise that inclusive investment leadership fuels stronger returns and enduring impact. Join our network of investors, leaders and innovators steering the future of life science investment. Because equity isn’t just financial, it’s foundational. Investing in tomorrow’s breakthroughs? Invest in Equity, today. #InvestInEquity #GenderEquity #Investment #LifeSciences

Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders. We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of our portfolio. We believe we have the team, track record and skill-set to capture the superior returns available from commercialising exceptional science.